RNA Insights

Eclipsebio
  • 0.0 (0)
  • Medicine
  • Updated Monthly

From mRNA vaccines to RNA-editing therapies, RNA and RNA-based therapeutics are the future of health and medicine — and new insights are made every day. In each episode of RNA Insights by Eclipsebio, host Grace Gudwien chats with a different RNA expert about their career and how their work has impacted RNA therapeutics and RNA research. We also review the latest RNA industry news and look forward to what's next in the world of RNA medicine.

Episodes

  1. 3d ago

    Episode 4: How RNA therapeutics can change the world of rare diseases with Dr. Tamar Grossman

    On this episode of RNA Insights, we chat with Dr. Tamar Grossman about her years of experience with ASOs and rare diseases, how she navigates multiple roles at once, and how new technologies are expediting the process of developing individualized RNA-based treatments.  Resources referenced in the episode:  Over-expression of DSCAM and COL6A2 cooperatively generates congenital heart defects: https://pubmed.ncbi.nlm.nih.gov/22072978/  Grossman’s publications: https://www.researchgate.net/profile/Tamar-Grossman-3 Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide: http://www.molvis.org/molvis/v23/561/ Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen: https://www.sciencedirect.com/science/article/pii/S0171298525000105?via%3Dihub  Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease: https://academic.oup.com/brain/article/144/10/2985/6276430 La Jolla Lab’s website: https://www.lajollalabs.ai/La Jolla Lab's email: info@lajollalabs.netThe n-of-1 clinical trial: The ultimate strategy for individualizing medicine?: https://pmc.ncbi.nlm.nih.gov/articles/PMC3118090/  La Jolla Labs, Inc. Announces First Patient Treated with Custom Antisense Therapy GBFsen for familial ALS: https://www.biospace.com/press-releases/la-jolla-labs-inc-announces-first-patient-treated-with-custom-antisense-therapy-gbfsen-for-familial-als  mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics: https://pmc.ncbi.nlm.nih.gov/articles/PMC12719227/  Harnessing RNA base editing for diverse applications in RNA biology and RNA therapeutics: https://pmc.ncbi.nlm.nih.gov/articles/PMC11979053/#Sec9  Women in Bio: https://womeninbio.org/  CEO Sisterhood: https://www.ceosisterhood.com/  Female Founders Fund: https://femalefoundersfund.com/  Music by Ievgen Poltavskyi from Pixabay  Sound Effect by Ribhav Agrawal from Pixabay  Eclipsebio host: Grace Finnell-Gudwien

  2. Jun 29

    Episode 3: Exploring nonsense-mediated decay and celebrating the RNA research community with Dr. Kristian Baker

    On this episode of RNA Insights, we chat with Dr. Kristian Baker about the relationship between nonsense-mediated decay and mRNA therapeutics as well as Baker's dual roles in research and science advocacy.  Resources referenced in the episode:  Ectopic RNase E sites promote bypass of 5'-end-dependent mRNA decay in Escherichia coli: https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2958.2003.03292.x  In vivo-compatible proximity labeling technologies: https://www.sciencedirect.com/science/article/abs/pii/S1367593126000165 Analysis of Nonsense-Mediated mRNA Decay in Saccharomyces cerevisiae: https://currentprotocols.onlinelibrary.wiley.com/doi/abs/10.1002/0471143030.cb2703s54  Single-Gene Disorders: https://www.ncbi.nlm.nih.gov/books/NBK132154/  Prime editing-installed suppressor tRNAs for disease-agnostic genome editing https://www.nature.com/articles/s41586-025-09732-2  Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome: https://www.cell.com/immunity/fulltext/S1074-7613(26)00075-0  RNA Society Journal: https://www.rnasociety.org/about-the-society/journal/ RNA Society website: https://www.rnasociety.org/ Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine: https://feeds.issuerdirect.com/news-release.html?newsid=5170330895753287&symbol=MRNA City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics: https://www.citytx.com/news/city-therapeutics-announces-99-5-million-series-b-financing-to-advance-next-generation-rnai-therapeutics  Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU): https://www.novartis.com/news/media-releases/novartis-remind-data-eaaci-show-rhapsido-potential-first-targeted-therapy-chronic-inducible-urticaria-cindu  Music by Ievgen Poltavskyi from Pixabay  Sound Effect by Ribhav Agrawal from Pixabay  Eclipsebio host: Grace Finnell-Gudwien

  3. May 28

    Episode 2: RNA helicases and the rise of mRNA therapeutics with Dr. Eckhard Jankowsky

    On this episode of RNA Insights, we chat with Dr. Eckhard Jankowsky about his work with RNA helicases and their impact on health, his transition from academia to Big Pharma, and how the past three decades of RNA therapeutic research will influence the future of RNA medicine.    Resources referenced in the episode:  The DEAH-box protein PRP22 is an ATPase that mediates ATP-dependent mRNA release from the spliceosome and unwinds RNA duplexes: https://pubmed.ncbi.nlm.nih.gov/9582286/   The DExH protein NPH-II is a processive and directional motor for unwinding RNA: https://pubmed.ncbi.nlm.nih.gov/10667799/   Jankowsky’s publications: https://scholar.google.com/citations?hl=en&user=z6F2cuoAAAAJ   More information on DDX3X: https://www.ncbi.nlm.nih.gov/gene/1654   More information on DDX3X syndrome: https://www.ucsf.edu/news/2020/03/416816/scientists-unravel-mystery-rare-genetic-disorder-causes-intellectual-disability  The Viral Protein K7 Inhibits Biochemical Activities and Condensate Formation by the DEAD-box Helicase DDX3X: https://www.sciencedirect.com/science/article/abs/pii/S0022283623003169   Hidden specificity in an apparently non-specific RNA-binding protein: https://pmc.ncbi.nlm.nih.gov/articles/PMC3800043/#S1    International mRNA Health Conference: https://mrna-conference.com/  AIRNA Presents New Preclinical Data on AATD Therapeutic Candidate AIR-001 and Cardiometabolic RNA-Editing Programs at ASGCT: https://airna.com/news/airna-presents-new-preclinical-data-on-aatd-therapeutic-candidate-air-001-and-cardiometabolic-rna-editing-programs-at-asgct/   Therorna to Showcase Clinical-Ready Circular RNA in vivo CAR-T and CircRNA Pipeline at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting: https://www.businesswire.com/news/home/20260511897230/en/Therorna-to-Showcase-Clinical-Ready-Circular-RNA-in-vivo-CAR-T-and-CircRNA-Pipeline-at-the-2026-American-Society-of-Gene-Cell-Therapy-ASGCT-Annual-Meeting   AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026: https://aviadobio.com/aviadobio-presents-positive-preclinical-data-for-avb-406-program-in-alzheimers-disease-and-other-tauopathies-at-asgct-2026/   Music by Ievgen Poltavskyi from Pixabay  Sound Effect by Ribhav Agrawal from Pixabay  Eclipsebio host: Grace Finnell-Gudwien

  4. Apr 30

    How eCLIP revolutionized RNA-based therapeutic research with Dr. Gene Yeo   

    Welcome to RNA Insights, an RNA therapeutics podcast hosted by Eclipsebio. Each month, we interview a different expert in the field of RNA and RNA-based medicine about their career and thoughts on the ever-evolving RNA therapeutic space.  On this inaugural episode, we talk with Dr. Gene Yeo, co-developer of the eCLIP protocol and co-founder of Eclipsebio, about his journey identifying the need for and developing a more efficient method of crosslinking immunoprecipitation that changed the ways scientists perform RNA research.  Resources referenced in the episode:  Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals: https://pubmed.ncbi.nlm.nih.gov/15285897/  Identification and analysis of alternative splicing events conserved in human and mouse: https://pubmed.ncbi.nlm.nih.gov/15708978/  Yeo Lab Publications: https://yeolab.com/publications   ENCODE Overview: https://www.encodeproject.org/help/project-overview/   Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP): https://www.nature.com/articles/nmeth.3810  Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics: https://www.circio.com/en/circio-enters-in-vivo-cell-therapy-evaluation-agreement-with-acuitas-therapeutics/  Afrigen Biologics Announces RSV mRNA Vaccine Collaboration: https://www.afrigen.co.za/news-press-release-events/  Immorna Announces First Evidence of Tissue B Cell Depletion with In Vivo CAR T JCXH 213 in Systemic Sclerosis Patient, Underscoring Platform’s Potential to Address Autoimmune Diseases: https://www.immornabio.com/News-details/41.html  Music by Ievgen Poltavskyi from Pixabay  Sound Effect by Ribhav Agrawal from Pixabay  Hosted by Grace Finnell-Gudwien

  • 4 Episodes

About

From mRNA vaccines to RNA-editing therapies, RNA and RNA-based therapeutics are the future of health and medicine — and new insights are made every day. In each episode of RNA Insights by Eclipsebio, host Grace Gudwien chats with a different RNA expert about their career and how their work has impacted RNA therapeutics and RNA research. We also review the latest RNA industry news and look forward to what's next in the world of RNA medicine.

Information

  • Creator
    Eclipsebio
  • Years Active
    2026
  • Episodes
    4
  • Rating
    Clean
  • Copyright
    © Eclipsebio
  • Show Website
    RNA Insights